The volume of building work in New Zealand grew robustly in the second quarter, with widespread strength seen throughout residential and non-residential elements. Given the huge construction sector pipeline, the positive trend is expected to continue, noted ANZ in a research report.
The volume of total building work grew 5.5 percent in sequential terms in the second quarter, after rising 5.7 percent in the first quarter. On a year-on-year basis, volumes grew 16 percent. The rise was broad based with similar-sized growth witnessed in residential and non-residential work.
Residential volumes were up 5.6 percent quarter-on-quarter. According to Statistics New Zealand, the trend level is almost double its low point in September 2011. Volumes of non-residential construction grew 5.3 percent in the second quarter, after rising 5.6 percent in the previous quarter.
In nominal terms, Auckland was leading. The value of building work in the region grew sharply by 13 percent, following a rise of 12 percent in the first quarter. Strong construction cost inflation is expected to be adding to this growth. Most other regions also registered solid growth, except Wellington, where the value of building work dropped 10 percent.


South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



